Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6858650 | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jul, 2022
(8 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6858650
(Pediatric) | PFIZER | Stable salts of novel derivatives of 3,3-diphenylpropylamines |
Jan, 2023
(2 months ago) | |
US8501723 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
US8088398 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
US7807715 | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Jun, 2027
(4 years from now) | |
US7807715
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
US8088398
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) | |
US8501723
(Pediatric) | PFIZER | Pharmaceutical compositions comprising fesoterodine |
Dec, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Jun 17, 2024 |
Pediatric Exclusivity (PED) | Dec 17, 2024 |
Market Authorisation Date: 31 October, 2008
Treatment: Treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Dosage: TABLET, EXTENDED RELEASE;ORAL
6
United States
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic